Niraparib tosylate monohydrate

Drug Overview

Niraparib tosylate monohydrate (Zejula®) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor approved for the treatment of certain advanced cancers. This targeted therapy is used to treat ovarian, fallopian tube, and primary peritoneal cancers, as well as recurrent or advanced prostate cancer. Niraparib tosylate monohydrate is a smart drug that exploits DNA repair deficiencies in cancer cells, leading to selective tumor cell death.

Generic name: Niraparib tosylate monohydrate
US Brand names: Zejula®
Drug Class: PARP inhibitor (Targeted Therapy)
Route of Administration: Oral tablet
FDA Approval Status: Approved for several oncological indications since 2017.​

What Is It and How Does It Work? (Mechanism of Action)

• PARP inhibition leads to the accumulation of DNA damage, which is especially toxic to cancer cells with deficiencies in homologous recombination repair, such as those with BRCA1 or BRCA2 mutations.
• The molecular action of niraparib involves binding to the catalytic domain of PARP, preventing the enzyme from repairing DNA single-strand breaks and leading to the formation of double-strand breaks.
• Cancer cells lacking functional BRCA1/2 cannot repair these double-strand breaks, resulting in synthetic lethality and selective tumor cell death.
• Niraparib’s selectivity for PARP minimizes off-target effects, making it a precision medicine for tumors with DNA repair deficiencies.
• The drug also modulates the tumor microenvironment by enhancing immune recognition of tumor cells, potentially improving response to immunotherapy.

FDA Approved Clinical Indications

Oncological uses

• Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
• Treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens.
• Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy, regardless of BRCA status.
• Treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer who have progressed following androgen receptor-directed therapy and a taxane-based chemotherapy.

Non-oncological uses

• None.

Dosage and Administration Protocols

Administer orally, with or without food. Swallow whole; do not crush or split. Monitor for hematologic and gastrointestinal side effects and adjust as needed.

Clinical Efficacy and Research Results

• Clinical trials (2020-2025) show that niraparib significantly improves progression-free survival (PFS) in patients with recurrent ovarian cancer.
• In the PRIMA trial, median PFS was 13.8 months for niraparib versus 8.2 months for placebo in patients with newly diagnosed advanced ovarian cancer.
• In the NOVA trial, median PFS was 21.0 months for BRCA-mutated patients and 9.3 months for non-BRCA-mutated patients, compared to 5.5 months for placebo.
• For prostate cancer, the MAGNITUDE trial demonstrated improved PFS in patients with HRR gene mutations, with median PFS of 16.6 months versus 10.9 months for placebo.
• Real-world data confirm niraparib’s ability to improve quality of life and reduce the need for further chemotherapy in refractory cases.
• Ongoing studies are evaluating niraparib in combination with other agents to further improve efficacy and expand its use to other cancers with DNA repair deficiencies.

Safety Profile and Side Effects

Common side effects (>10%)

• Nausea, fatigue, thrombocytopenia, anemia, neutropenia, constipation, vomiting, headache, diarrhea, abdominal pain, decreased appetite.
• Management: Symptomatic care (antiemetics, blood transfusions, dose interruptions or reductions).

Serious adverse events

• Hematologic toxicity (thrombocytopenia, anemia, neutropenia).
• Gastrointestinal perforation (rare).
• Management: Withhold or discontinue for severe hematologic toxicity or gastrointestinal perforation. Monitor for signs of infection or bleeding. Use supportive care and multidisciplinary consultation for severe adverse events.
• Additional rare but severe reactions include pneumonitis and hypersensitivity reactions.

No Black Box Warning.

Connection to Stem Cell and Regenerative Medicine

• DNA Repair Pathway Exploitation: Niraparib embodies the principle of synthetic lethality, a key concept in Targeted Therapy development. It targets the poly(ADP-ribose) polymerase (PARP) enzyme, exploiting the cancer cell’s intrinsic defect in the homologous recombination repair (HRR) pathway (e.g., due to BRCA mutations). This mechanism is an advanced way to target the cell’s internal regenerative (DNA repair) machinery for destruction.
• Hematologic Impact on Stem Cells: While Niraparib is not a cellular therapy, its most significant adverse effect, severe myelosuppression (anemia, neutropenia, thrombocytopenia), directly impacts hematopoietic stem and progenitor cells in the bone marrow. This highlights the close link between DNA repair mechanisms and the regenerative capacity of the blood-forming system.
• Research in Combination Therapy: Current research is exploring combinations of PARP inhibitors like Niraparib with therapies aimed at increasing the genomic instability of cancer cells or sensitizing them to other forms of therapy, aligning with the goals of advanced regenerative medicine and targeted oncology.

Patient Management and Practical Recommendations

Pre-treatment tests

• Baseline: CBC, LFTs, renal function, ECG; imaging (CT or MRI) for tumor staging.
• Assess for pre-existing hematologic and gastrointestinal disorders.

Precautions during treatment

• Monitor for hematologic and gastrointestinal side effects every 2-4 weeks; educate on symptoms (fatigue, bruising, severe diarrhea, abdominal pain).
• Avoid live vaccines; use contraception (embryo-fetal toxicity).

Do’s and Don’ts

• DO report new or worsening hematologic or gastrointestinal symptoms immediately.
• DO maintain hydration and nutrition during treatment.
• DO use supportive care for hematologic toxicity.
• DON’T use concurrent medications that increase risk of bleeding or myelosuppression.
• DON’T breastfeed during treatment and 5 months after last dose.

Legal Disclaimer

This guide is for informational purposes only and is intended for international patients and healthcare professionals. It does not replace professional medical advice, diagnosis, or treatment. Dosing and protocols may vary by patient status and local regulatory guidelines. Always consult with a qualified oncologist or healthcare provider regarding specific medical conditions.